Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S. Taro Pharmaceutical Industries Ltd. announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®. When distribution begins, Taro’s deferiprone tablets will be dispensed by BioPlus® Specialty Pharmacy. For more information on transferring your prescription, visit Taro Cares at www.tarocares.com or call 1-888-292-0744 to speak with a pharmacist. Living With Superficial Siderosis is not a medical provider or health care facility and thus can neither diagnose Superficial Siderosis or associated symptoms nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified healthcare professionals before seeking any information related to your particular diagnosis or treatment of Superficial Siderosis or associated symptoms
Visit the Superficial Siderosis Pateint Registry. Open to patients, caregivers, and researchers worldwide. This registry offers you a chance to participate in research surveys and trial announcements.
Visit the official SSRA Gear store. The proceeds of every purchase helps fund the Superficial Siderosis Research Alliance research grant, education, and awareness programs.
Hearing Impaired 5PK
PLEASE VOTE WEEKLY
BLOG: Superficial Siderosis Research Alliance
SUPERFICIAL SIDEROSIS RESEARCH ALLIANCE